Salvador Payán Pernía: Arguing against a Significant Role for Erythropoietin Analogues in the Management of PRCA
Salvador Payán Pernía, Member of the Board of Directors of the Erythropathology Group at Spanish Society of Hematology and Hemotherapy (SEHH), shared on LinkedIn about a recent article he and his co-authord, published in Blood Advances, adding:
“I’m delighted to have contributed to this European multicentre study on acquired pure red cell aplasia (PRCA), one of the rare diseases I most enjoy managing.
Acquired PRCA is an underrecognized entity, even among hematologists, as reflected by the median time from presentation to treatment of 2 months (range: 1–204 months) observed in our study.
PRCA should be promptly suspected in any patient with severe anemia and a low reticulocyte count. In our study, earlier initiation of cyclosporine A was associated with a better response.
Our study also shows that PRCA is characterized by markedly elevated erythropoietin levels (median: 908 mIU/mL; range: 29–3000 mIU/mL), likely related to reduced degradation by erythroblasts.
These findings argue against a significant role for erythropoietin analogues in the management of PRCA.
At diagnosis, most patients had elevated ferritin levels and transferrin saturation, reflecting rapid iron accumulation and reduced iron utilization.
Reticulocytes are crucial not only for diagnosis but also as an early marker of response, as highlighted in the paper –look at the reticulocytes!
Thanks to Bruno Fattizzo and Francesco Versino for their initiative, leadership, and excellent work.”
Title: Clinical Heterogeneity and Outcome of acquired PRCA: a Multicenter European Study
Authors: Francesco Versino,Marc Michel,Jennifer Vidler, Salvador Payán-Pernía,Roochi Trikha,Shreyans A Gandhi,Sukanya Gogoi,Manujasr, Wimalachandra,Omar Racchi,Maria Teresa Lupo-Stanghellini,Sabrina Giammarco,Maria Arguello Marina,Mara Memoli,Andreas Glenthøj,Gabriele Merati, Yamuna Wasanthi Wickramasinghe,Aparna Chitharanjan,Mylene Hemmer,Mariasanta Napolitano,Margarita Jimenez-Jambrina,Filippo Brioschi, Antonio Palma-Vallelano,Tomas Jose Gonzalez-Lopez,Cristina Clissa,Marta Bortolotti,Giacinto Luca Pedone,Giorgio Alberto Croci,Francesco Passamonti, Wilma Barcellini, Austin G Kulasekararaj, Bruno Fattizzo
Stay updated on all scientific advances with Hemostasis Today.
-
Jul 24, 2026, 08:58Aryabhatta Sadhu: Advancing Patient Blood Management with Rational Transfusion
-
Jul 24, 2026, 08:58Vikash Jaiswal: Toward Better ASCVD Risk Assessment for South Asian Populations
-
Jul 24, 2026, 08:57Wolfgang Miesbach: Human Tissue Study Sheds Light on AAV Gene Therapy Safety
-
Jul 24, 2026, 08:57Muna Adam: Plasma-Derived Factor X Concentrate Used in First UAE Roma Variant Cases
-
Jul 24, 2026, 08:32Cedric Stephane Fosso: Every Drop of Blood Matters – A Child’s Silent Cry for Hemophilia Awareness
-
Jul 24, 2026, 08:19Afila Thasnim EK: Blood Grouping Discrepancies – A Critical Challenge in Transfusion Medicine
-
Jul 24, 2026, 05:15Jade Morrissey: Grateful to Present My PhD Research in Immunothrombosis at ISTH 2026
-
Jul 24, 2026, 05:04Moustafa Abdou: Unmasking Pure Red Cell Aplasia
-
Jul 24, 2026, 04:53Ana Pedrero Gil: The Future of Blood-Derived Therapies